
Model Viruses
The selection of model viruses for the purpose of validation
is critical and must take into account the nature and origin of the producer
cell line; the model virus should be close to identical to a virus suspected
in the cell line, or closely related to viruses that might infect the
cell, e.g. retroviruses for recombinant or hybridoma cells.
In order to achieve a maximum reduction factor for virus, the model
virus should be grown to high titers and should be detectable in a simple
but sensitive assay. Care has to be taken when concentrating a virus
solution in order to increase the volumetric titer: the aggregation of
viral particles might lead to an increased but not relevant mechanical
removal by means of filtration, or a decrease in inactivation due to
protection of viral particles in the core of the aggregate.
Typically, the removal or inactivation of virus is described as "log 10
reduction", i.e. the decadic logarithm of the titer reduction.
With regard to a potential infection by an unknown virus, the model
viruses for the validation of virus clearance have to cover a broad range
of virus features.
| Virus
Features |
Feasibility |
| size and shape
of virus
enveloped/non-enveloped
genome structure DNA/RNA
strandedness of genome
resistance to inactivation |
relevance for
production
achievable high tier
high sensitivity of detection
ease of detection |
Selection criteria for the choice of model viruses
|
Virus |
Family |
Genus |
Natural host |
Genome |
Envelope |
Size |
Shape |
Resis-
tance |
|
Vesicular stomatitis virus |
Rhabdo |
Vesiculo-virus |
Equine
Bovine |
RNA |
yes |
70x175 nm |
Bullet |
Low |
|
Parainfluenza virus |
Paramyxo |
Paramyxo-virus |
Various |
RNA |
yes |
100-200+ nm |
Pleomorph Spherical |
Low |
|
MuLV |
Retro |
Type C oncovirus |
Mouse |
RNA |
yes |
80 - 110 nm |
Spherical |
Low |
|
Sindbis virus |
Toga |
Alphavirus |
Human |
RNA |
yes |
60 - 70 nm |
Spherical |
Low |
|
BVDV |
Flavi |
Pestivirus |
Bovine |
RNA |
yes |
50 - 70 nm |
Pleomorph Spherical |
Low |
|
Pseudorabies |
Herpes |
|
Swine |
DNA |
yes |
120 - 200 nm |
Spherical |
Medium |
|
Poliovirus Sabin
Type 1 |
Picorna |
Enterovirus |
Human |
RNA |
no |
25 - 30 nm |
Icosahedral |
Medium |
|
Encephalomyo-
carditis virus (EMC) |
Picorna |
Cardiovirus |
Mouse |
RNA |
no |
25 - 30 nm |
Icosahedral |
Medium |
|
Reovirus 3 |
Reo |
Orthoreo-
virus |
Various |
RNA |
no |
60 - 80 nm |
Spherical |
Medium |
|
SV 40 |
Papova |
Polyoma-
virus |
Monkey |
DNA |
no |
40 -50 nm |
Icosahedral |
Very
high |
|
Paroviruses
(canine, porcine) |
Parvo |
Parvo-
virus |
Canine
Porcine |
DNA |
no |
18-24 nm |
Icosahedral |
Very
high |
Selection of model viruses for validation studies
Resistance to physico-chemical treatments based on studies of
production processes. Resistance is relative to the specific treatment and
it is used in the context of the understanding of the biology of the virus
and the nature of the manufacturing process. Actual results will vary
according to the treatment. These viruses are examples only and their use
is not mandatory [from: ICH Q5A].
As a rule process validation has to be performed at the manufacturing
scale, using equipment of identical type and size. The contamination of
manufacturing equipment with virus is evidently not desireful and
depending on the manufacturing scale even not technically feasible.
Therefore two strategies are accepted for the validation work with
virus:
- the use of a replica for a small scale production or
- a linear downscaled model of the manufacturing equipment, on
condition that all relevant process parameters are fully representative
for the production scale.